AUG 7, 2026 · JOURNAL ARTICLE
Inhibition of HOX/PBX Dimers as a Potential Therapeutic Strategy in Breast Cancer Subtypes Including Triple Negative Breast Cancer
Current Issues in Molecular Biology
A sound preclinical study demonstrating HTL-001 efficacy in TNBC cell lines and a mouse xenograft model, but lacking human clinical data and powered efficacy trials needed to establish clinical utility.
Study details
DesignPreclinical in vitro and in vivo study
InterventionHTL-001, a HOX/PBX interaction inhibitor; o…
ComparatorImmortalised normal breast cells; vehicle o…